EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-World Osteoporosis Treatment Gap and Costs in Spain: Data from Women with a First Fragility Fracture or Diagnosis of Postmenopausal Osteoporosis

Antoni Sicras-Mainar, Francesc Sorio-Vilela, Marta Sacrest-Soy, Sonia Gatell, Aram Sicras-Navarro, Renata Villoro-Valdés, Elena Rebollo-Gómez, Ignacio Hernández

Rheumatology and Therapy · 2025-04 · 12 (2) · 315-335

DOI: 10.1007/s40744-024-00743-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology and Therapy, online erschienen am 11.02.2025. Verfasst von Antoni Sicras-Mainar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Atrys Health, Barcelona, Spain. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Postmenopausal osteoporosis (PMO) increases the risk of fragility fractures (FF), leading to disability, higher mortality, and elevated healthcare costs. Despite available treatments, osteoporosis (OP) remains undertreated, especially in women over 50 years at high risk for FF. Real-world data on OP care in Spain are limited. This study aims to assess the OP treatment gap, healthcare resource utilisation (HCRU), and costs among Spanish women following a first FF or PMO diagnosis. METHODS: This retrospective study used data from the BIG-PAC® administrative database on women aged ≥ 50 years with a first FF (cohort 1) or newly diagnosed PMO (cohort 2) between 2014 and 2018. Patients were followed for 2 years after the index event. The primary outcome was the proportion of women not prescribed OP medication within 6 months after the index event (treatment gap). Secondary outcomes included fracture incidence, mortality, HCRU, and costs. RESULTS: The study included 22,142 women: 3190 in cohort 1 and 18,952 in cohort 2. The OP treatment gap was higher in cohort 1 vs cohort 2 (41.5% vs 23.6%). In cohort 1, 59.2% were diagnosed with PMO after the first FF, with 88% experiencing subsequent fracture(s). OP treatment persistence decreased over time in both cohorts. Fracture rates were lower in women prescribed OP treatment vs those who were not (8.35 vs 13.8 per 1000 patient-years) and in those who showed 24-month-persistence and 12-month adherence to treatment vs those who did not (8.98 and 7.66 vs 10.79 and 10.76). The 2-year mean cost per patient was higher in cohort 1 (€10,601) than in cohort 2 (€1659), with the highest costs incurred for hip (€15,833) and vertebral (€10,593) fractures. CONCLUSION: This study highlights a significant treatment gap in Spanish women aged ≥ 50 with a first FF or newly diagnosed PMO. Costs are particularly high for those with a first FF, especially for hip or vertebral fractures. Improving treatment adherence could reduce fracture risk, healthcare costs, and resource utilisation.

Schlagwörter

Stichwörter der Autor:innen

Fragility fractureHCRUHealthcare costsHealthcare resource utilizationPostmenopausal osteoporosisReal-worldTreatment gap

Autor:innen und Institutionen

  • Atrys Health, Barcelona, Spain.
  • Amgen (Europe) GmbH, Rotkreuz, Switzerland.
  • Amgen SA, Barcelona, Spain.
  • Health Economics and Outcomes Research, Atrys Health, c/Príncipe de Vergara 132, 28002, Madrid, Spain.
  • Health Economics and Outcomes Research, Atrys Health, c/Príncipe de Vergara 132, 28002, Madrid, Spain. ihernandez@atryshealth.com.

Förderung

  • Amgen

Zitieren

APA

Sicras-Mainar, A., Sorio-Vilela, F., Sacrest-Soy, M., Gatell, S., Sicras-Navarro, A., Villoro-Valdés, R., Rebollo-Gómez, E., & Hernández, I. (2025). Real-World Osteoporosis Treatment Gap and Costs in Spain: Data from Women with a First Fragility Fracture or Diagnosis of Postmenopausal Osteoporosis. Rheumatology and Therapy, 12(2), 315-335. https://doi.org/10.1007/s40744-024-00743-5

Vancouver

Sicras-Mainar A, Sorio-Vilela F, Sacrest-Soy M, Gatell S, Sicras-Navarro A, Villoro-Valdés R, et al. Real-World Osteoporosis Treatment Gap and Costs in Spain: Data from Women with a First Fragility Fracture or Diagnosis of Postmenopausal Osteoporosis. Rheumatology and Therapy. 2025;12(2):315-335. doi:10.1007/s40744-024-00743-5

BibTeX
@article{SicrasMainar2025,
  author = {Sicras-Mainar, Antoni and Sorio-Vilela, Francesc and Sacrest-Soy, Marta and Gatell, Sonia and Sicras-Navarro, Aram and Villoro-Valdés, Renata and Rebollo-Gómez, Elena and Hernández, Ignacio},
  title = {Real-World Osteoporosis Treatment Gap and Costs in Spain: Data from Women with a First Fragility Fracture or Diagnosis of Postmenopausal Osteoporosis},
  journal = {Rheumatology and Therapy},
  year = {2025},
  volume = {12},
  number = {2},
  pages = {315--335},
  doi = {10.1007/s40744-024-00743-5}
}
Kostenlos starten →